MCID: PRP021
MIFTS: 39

Peripheral Nervous System Neoplasm

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Peripheral Nervous System Neoplasm

MalaCards integrated aliases for Peripheral Nervous System Neoplasm:

Name: Peripheral Nervous System Neoplasm 12 15
Peripheral Nervous System Neoplasms 43 71
Nerve Sheath Neoplasm 12 74
Nerve Sheath Tumors 12 71
Neoplasm of Peripheral Nerve 12
Nerve Sheath Neoplasms 43
Tumor of Pns 12

Classifications:



External Ids:

Disease Ontology 12 DOID:1192
NCIt 49 C3321 C4972
UMLS 71 C0031118 C0206727

Summaries for Peripheral Nervous System Neoplasm

Disease Ontology : 12 A nervous system cancer that is located in the peripheral nervous system.

MalaCards based summary : Peripheral Nervous System Neoplasm, also known as peripheral nervous system neoplasms, is related to autonomic nervous system neoplasm and neuroblastoma, and has symptoms including neuralgia An important gene associated with Peripheral Nervous System Neoplasm is MIR34A (MicroRNA 34a), and among its related pathways/superpathways are DNA Damage Response and MicroRNAs in cancer. The drugs Mechlorethamine and Ifosfamide have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and cervix.

Wikipedia : 74 A nerve sheath tumor is a type of tumor of the nervous system (nervous system neoplasm) which is made up... more...

Related Diseases for Peripheral Nervous System Neoplasm

Diseases in the Peripheral Nervous System Neoplasm family:

Peripheral Nervous System Benign Neoplasm

Diseases related to Peripheral Nervous System Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 445)
# Related Disease Score Top Affiliating Genes
1 autonomic nervous system neoplasm 32.5 MYCN MIR9-1 MIR542 MIR380 MIR34C MIR34A
2 neuroblastoma 31.6 NF1 MYCN MIR34A MIR181A1 MIR17 MIR125A
3 glioma 31.3 NF1 MIR34A MIR20A MIR19A MIR17
4 renal cell carcinoma, nonpapillary 31.0 MIR9-1 MIR34A MIR335 MIR27A MIR199A1 MIR17
5 retroperitoneal neuroblastoma 30.9 MYCN MIR34A
6 thyroid gland papillary carcinoma 30.9 MIR9-1 MIR199A1 MIR181A1 MIR17 MIR125A
7 lymphoma, non-hodgkin, familial 30.9 MYCN MIR9-1 MIR34A MIR338 MIR27A MIR20A
8 melanoma, uveal 30.9 NF1 MIR9-1 MIR199A1 MIR149 H2AC18
9 demyelinating disease 30.9 MIR9-1 MIR338 MIR27A H2AC18
10 melanoma 30.8 MIR34C MIR34A MIR338 MIR27A MIR19A MIR181A1
11 lung cancer susceptibility 3 30.8 NF1 MIR9-1 MIR542 MIR338 MIR199A1 MIR17
12 diffuse large b-cell lymphoma 30.8 MIR199A1 MIR181A1 MIR17 MIR149
13 endometriosis 30.8 MIR34C MIR20A MIR199A1 MIR125A
14 cervical cancer 30.8 MIR9-1 MIR34C MIR34A MIR338 MIR27A MIR20A
15 nasopharyngeal carcinoma 30.8 MIR9-1 MIR34C MIR338 MIR17 MIR125A
16 kidney cancer 30.7 MIR27A MIR20A MIR199A1 MIR17
17 connective tissue cancer 30.6 MIR9-1 MIR542 MIR338 MIR335 MIR27A MIR20A
18 gastrointestinal system cancer 30.5 MIR9-1 MIR542 MIR34C MIR34A MIR338 MIR335
19 lung cancer 30.4 MYCN MIR9-1 MIR542 MIR34C MIR34A MIR338
20 familial retinoblastoma 30.3 NF1 MYCN
21 epithelioid malignant peripheral nerve sheath tumor 12.7
22 malignant peripheral nerve sheath tumor with perineurial differentiation 12.6
23 malignant melanocytic peripheral nerve sheath tumor of mediastinum 12.5
24 malignant cardiac peripheral nerve sheath neoplasm 12.5
25 neurofibrosarcoma 12.2
26 malignant melanocytic neoplasm of the peripheral nerve sheath 12.0
27 neurofibromatosis, type i 11.8
28 malignant glandular tumor of peripheral nerve sheath 11.7
29 malignant triton tumor 11.4
30 melanocytic psammomatous mpnst 11.4
31 chromosome 17q11.2 deletion syndrome, 1.4-mb 11.3
32 chromosome 17q11.2 deletion syndrome 11.3
33 painful orbital and systemic neurofibromas-marfanoid habitus syndrome 11.3
34 autonomic nervous system benign neoplasm 10.8 NF1 MYCN KDM4C
35 central nervous system benign neoplasm 10.8 NF1 MYCN MIR34A KDM4C H2AC18
36 peripheral nervous system benign neoplasm 10.8 NF1 MYCN KDM4C
37 thyroid gland anaplastic carcinoma 10.8 MIR34C MIR19A MIR17
38 skeletal muscle cancer 10.8 NF1 MYCN MIR199A1 H2AC18
39 muscle cancer 10.8 NF1 MYCN MIR9-1 MIR199A1 H2AC18
40 feingold syndrome 1 10.8 MYCN MIR20A MIR19A MIR17
41 fetal alcohol spectrum disorder 10.8 MIR9-1 KDM4C H2AC18
42 fibrillary astrocytoma 10.8 NF1 KDM4C H2AC18
43 testicular disease 10.8 MIR199A1 MIR181A1 KDM4C H2AC18
44 gastrointestinal system benign neoplasm 10.8 MIR20A MIR199A1 MIR17 H2AC18
45 lymphatic system disease 10.8 MIR17 MIR125A KDM4C H2AC18
46 fetal alcohol syndrome 10.8 MIR9-1 KDM4C H2AC18
47 intestinal benign neoplasm 10.8 MIR20A MIR199A1 MIR17 KDM4C H2AC18
48 chromosome 16p13.3 deletion syndrome, proximal 10.8 MIR9-1 KDM4C H2AC18
49 inherited metabolic disorder 10.8 MIR9-1 MIR199A1 MIR17 H2AC18
50 facioscapulohumeral muscular dystrophy 1 10.8 MIR34A MIR335 KDM4C H2AC18

Graphical network of the top 20 diseases related to Peripheral Nervous System Neoplasm:



Diseases related to Peripheral Nervous System Neoplasm

Symptoms & Phenotypes for Peripheral Nervous System Neoplasm

UMLS symptoms related to Peripheral Nervous System Neoplasm:


neuralgia

Drugs & Therapeutics for Peripheral Nervous System Neoplasm

Drugs for Peripheral Nervous System Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 75)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mechlorethamine Approved, Investigational Phase 2, Phase 3 51-75-2 4033
2
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
3
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
4
Daunorubicin Approved Phase 2, Phase 3 20830-81-3 30323
5
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
6 Antibiotics, Antitubercular Phase 2, Phase 3
7 Anti-Bacterial Agents Phase 2, Phase 3
8 Alkylating Agents Phase 2, Phase 3
9
Isophosphamide mustard Phase 2, Phase 3 0
10 Topoisomerase Inhibitors Phase 2, Phase 3
11
Liposomal doxorubicin Phase 2, Phase 3 31703
12 Protein Kinase Inhibitors Phase 2, Phase 3
13 Imatinib Mesylate Phase 2, Phase 3 220127-57-1 123596
14
Bevacizumab Approved, Investigational Phase 2 216974-75-3
15
Xylometazoline Approved, Investigational Phase 1, Phase 2 526-36-3 5709
16
Etoposide Approved Phase 2 33419-42-0 36462
17
Lenograstim Approved, Investigational Phase 2 135968-09-1
18
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
19
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
20
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
21
Pirfenidone Approved, Investigational Phase 2 53179-13-8 40632
22
Talazoparib Approved, Investigational Phase 1, Phase 2 1207456-01-6 135565082
23
Temozolomide Approved, Investigational Phase 1, Phase 2 85622-93-1 5394
24
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
25
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
26
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
27
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
28
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492 6473866
29
nivolumab Approved Phase 2 946414-94-4
30
Ipilimumab Approved Phase 2 477202-00-9
31
Mesna Approved, Investigational Phase 2 3375-50-6 598
32
Adenosine Approved, Investigational Phase 2 58-61-7 60961
33
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
34
Pembrolizumab Approved Phase 2 1374853-91-4
35
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
36
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
37
Threonine Approved, Nutraceutical Phase 2 72-19-5 6288
38
Tyrosine Approved, Investigational, Nutraceutical Phase 1, Phase 2 60-18-4 6057
39 Lorvotuzumab mertansine Investigational Phase 2 1008106-64-6
40 Angiogenesis Inhibitors Phase 2
41
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
42 Adjuvants, Immunologic Phase 2
43 Etoposide phosphate Phase 2
44 Anti-Inflammatory Agents Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Anti-Inflammatory Agents, Non-Steroidal Phase 2
47 Antirheumatic Agents Phase 2
48 Analgesics Phase 2
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1, Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754) Completed NCT02180867 Phase 2, Phase 3 Doxorubicin;Doxorubicin Hydrochloride;Ifosfamide;Pazopanib;Pazopanib Hydrochloride
2 An Open-label Multicenter Phase II Study of Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors Terminated NCT00427583 Phase 2, Phase 3 imatinib mesylate
3 Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors Completed NCT01661283 Phase 2 everolimus;bevacizumab
4 U.S./Canada Sarcoma Intergroup Study of OSI-774 in Malignant Peripheral Nerve Sheath Tumors, Phase II Completed NCT00068367 Phase 2 erlotinib hydrochloride
5 A Phase I/II Trial of Ganetespib in Combination With the mTOR Inhibitor Sirolimus for Patients With Recurrent or Refractory Sarcomas Including Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Completed NCT02008877 Phase 1, Phase 2 ganetespib;Sirolimus
6 Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated High Grade Malignant Peripheral Nerve Sheath Tumors Completed NCT00304083 Phase 2 doxorubicin hydrochloride;etoposide;ifosfamide
7 A Phase II Trial of Dasatinib in Advanced Sarcomas Completed NCT00464620 Phase 2 Dasatinib
8 Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma Completed NCT00837148 Phase 2 Sorafenib and Dacarbazine
9 Phase II Study of MLN8237 in Advanced/Metastatic Sarcoma Completed NCT01653028 Phase 2 Alisertib
10 Phase II Trial of Pirfenidone in Children, Adolescents, and Young Adults With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas Completed NCT00076102 Phase 2 Pirfenidone
11 A Phase 1/2 Study of BMN 673, an Oral Poly(ADP-Ribose) Polymerase Inhibitor, Plus Temozolomide in Children With Refractory or Recurrent Malignancies Completed NCT02116777 Phase 1, Phase 2 Talazoparib;Temozolomide
12 A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Completed NCT01614795 Phase 2 Temsirolimus
13 A Phase 1B/II Study of GDC-0449 (NSC 747691) in Combination With RO4929097, a Gamma-Secretase Inhibitor (GSI) in Advanced/Metastatic Sarcomas Completed NCT01154452 Phase 1, Phase 2 Gamma-Secretase Inhibitor RO4929097;Vismodegib
14 A Single Arm, Multicenter Phase II a Trial of RAD001 as Monotherapy in the Treatment of Neurofibromatosis 1 Related Internal Plexiform Neurofibromas That Cannot be Removed by Surgery Completed NCT01412892 Phase 2 RAD001: Everolimus
15 A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas Completed NCT00634270 Phase 2 Sirolimus
16 SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors Recruiting NCT03433183 Phase 2 Selumetinib;Sirolimus
17 Phase I Study Evaluating Combination Therapy With the Receptor Tyrosine Kinase Inhibitor PLX3397 and Sirolimus in Patients With Unresectable Sarcoma and Phase II Study in Malignant Peripheral Nerve Sheath Tumors Recruiting NCT02584647 Phase 1, Phase 2 PLX3397;Sirolimus
18 A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors Recruiting NCT03872427 Phase 2 Glutaminase Inhibitor CB-839 Hydrochloride
19 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
20 A Phase 2b Trial of the MEK 1/2 Inhibitor (MEKi) PD-0325901 in Adult and Pediatric Patients With Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) That Are Causing Significant Morbidity Recruiting NCT03962543 Phase 2 PD-0325901 oral capsule
21 A Non-Inferiority Study of Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Recruiting NCT02584309 Phase 2 Dexrazoxane;Doxorubicin
22 Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Recruiting NCT03651375 Phase 2 Sequential chemotherapy - 3 courses of AI
23 Preoperative Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Recruiting NCT03989596 Phase 2
24 Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas Recruiting NCT02407405 Phase 2 Selumetinib
25 A Phase II Study of Cabozantinib (XL184) for Plexiform Neurofibromas in Subjects With Neurofibromatosis Type 1 in Children and Adults Recruiting NCT02101736 Phase 2 Cabozantinib
26 A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma Active, not recruiting NCT02452554 Phase 2
27 A Phase II Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery Active, not recruiting NCT02691026 Phase 2 Pembrolizumab
28 A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma Active, not recruiting NCT02601209 Phase 1, Phase 2 Pazopanib;Pazopanib Hydrochloride;Sapanisertib
29 A Randomized, Double-Blind Phase II, Study of Gemcitabine Alone or in Combination With Pazopanib for Refractory Soft Tissue Sarcoma Active, not recruiting NCT01532687 Phase 2 Gemcitabine Hydrochloride;Pazopanib Hydrochloride
30 A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN) Active, not recruiting NCT01362803 Phase 1, Phase 2 AZD6244
31 A Phase IB/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) Terminated NCT01418001 Phase 1, Phase 2 Pazopanib 400 mg QD - Gemcitabine and Docetaxel in Combination
32 A Phase 2 Study of CPI-0610, a Small Molecule Inhibitor of Bromodomain and Extra-Terminal (BET) Proteins, in Patients With Malignant Peripheral Nerve Sheath Tumors Withdrawn NCT02986919 Phase 2 CPI-0610
33 A Phase I, Open-Label, Dose Escalation Study of JX-594 (Vaccinia GM-CSF/Thymidine Kinase-Deactivated Virus) Administered by Intratumoral Injection in Pediatric Patients With Unresectable Refractory Solid Tumors. Completed NCT01169584 Phase 1 Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
34 A Phase 1 Study of Doxorubicin and A12 in Advanced Soft Tissue Sarcoma Completed NCT00720174 Phase 1 Doxorubicin Hydrochloride
35 A Phase I Dose Escalation Study of Intratumoral or Intravenous Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory Non-Central Nervous System (Non-CNS) Solid Tumors Completed NCT00931931 Phase 1
36 Phase I Trial of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, Nexavar) in Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas Completed NCT00727233 Phase 1 Nexavar (BAY 43-9006) (Sorafenib);Toxicity, Pharmacokinetics;Pharmacodynamics;Radiographic Evaluation;QOL assessment, Neuropsychological;Bony Toxicity
37 Transformation of Plexiform Neurofibromas to Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1: Clinical, Histopathologic, and Genomic Analysis Recruiting NCT02211768 Phase 1 [18F]-FLT-PET/CT scans
38 Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Unresectable or Recurrent Malignant Peripheral Nerve Sheath Tumor Recruiting NCT02700230 Phase 1
39 Phase I Study of EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults Recruiting NCT03618381 Phase 1
40 A Phase 1B Study of Ribociclib in Combination With Doxorubicin in Advanced Soft Tissue Sarcomas Active, not recruiting NCT03009201 Phase 1 Doxorubicin;Ribociclib
41 A Phase I Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor in Combination With the Proteasome Inhibitor Ixazomib for the Treatment of Advanced Sarcoma Not yet recruiting NCT03880123 Phase 1 Selinexor;Ixazomib
42 Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis Unknown status NCT01777451
43 Analysis of Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients Unknown status NCT01218139
44 Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors Recruiting NCT03141021
45 Natural History Study and Longitudinal Assessment of Children, Adolescents, and Adults With Neurofibromatosis Type 1 Recruiting NCT00924196
46 Observational Study on Multisession Radiosurgery for Optic Nerve Sheath Meningiomas Recruiting NCT02594709
47 BLESSED: Expanded Access for DeltaRex-G for Advanced Solid Tumors, Lymphoma and Multiple Myeloma Available NCT04091295 DeltaRex-G
48 Spinal Tumor Proton Protocol Withdrawn NCT01567787

Search NIH Clinical Center for Peripheral Nervous System Neoplasm

Cochrane evidence based reviews: peripheral nervous system neoplasms

Genetic Tests for Peripheral Nervous System Neoplasm

Anatomical Context for Peripheral Nervous System Neoplasm

MalaCards organs/tissues related to Peripheral Nervous System Neoplasm:

40
Thyroid, Bone, Cervix, B Cells, Brain, Skin, Prostate

Publications for Peripheral Nervous System Neoplasm

Articles related to Peripheral Nervous System Neoplasm:

# Title Authors PMID Year
1
Health effects associated with chronic exposure to low-level hydrogen sulfide from geothermoelectric power plants. A residential cohort study in the geothermal area of Mt. Amiata in Tuscany. 61
31096427 2019
2
Recent Advances in the Diagnosis and Pathogenesis of Neurofibromatosis Type 1 (NF1)-associated Peripheral Nervous System Neoplasms. 61
29762158 2018
3
A primitive neuroectodermal tumor with extension into the cranial vault in a dog. 61
22547846 2011
4
Brain Tumors in Neurofibromatosis. 61
12670408 2003
5
Immunohistochemical diagnosis of nervous system neoplasms. 61
2184976 1990

Variations for Peripheral Nervous System Neoplasm

Expression for Peripheral Nervous System Neoplasm

Search GEO for disease gene expression data for Peripheral Nervous System Neoplasm.

Pathways for Peripheral Nervous System Neoplasm

Pathways related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.99 MIR20A MIR19A MIR181A1 MIR17
2 11.89 MIR9-1 MIR34C MIR34A MIR335 MIR27A MIR20A
3 11.28 MIR34C MIR338 MIR20A MIR19A MIR17
4 11.16 MIR542 MIR34C MIR27A MIR181A1
5 11.01 MIR9-1 MIR199A1 MIR181A1

GO Terms for Peripheral Nervous System Neoplasm

Cellular components related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR338 MIR335 MIR27A MIR20A MIR19A MIR199A1

Biological processes related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.87 MYCN MIR338 MIR27A MIR20A MIR181A1 MIR17
2 negative regulation of inflammatory response GO:0050728 9.78 MIR20A MIR19A MIR181A1 MIR149
3 negative regulation of cell migration GO:0030336 9.77 NF1 MIR9-1 MIR34A MIR338 MIR149
4 negative regulation of angiogenesis GO:0016525 9.74 NF1 MIR34A MIR125A
5 negative regulation of protein kinase B signaling GO:0051898 9.7 MIR34C MIR34A MIR20A
6 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.69 MIR27A MIR20A MIR17
7 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.67 MIR20A MIR19A MIR199A1
8 miRNA mediated inhibition of translation GO:0035278 9.63 MIR9-1 MIR27A MIR20A MIR181A1 MIR17 MIR103A1
9 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.61 MIR27A MIR199A1 MIR17
10 positive regulation of connective tissue replacement GO:1905205 9.58 MIR34C MIR34A MIR199A1
11 positive regulation of cardiac muscle cell apoptotic process GO:0010666 9.56 MIR34A MIR17
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.56 MIR34C MIR20A MIR199A1 MIR17
13 negative regulation of toll-like receptor signaling pathway GO:0034122 9.55 MIR19A MIR17
14 positive regulation of cell growth involved in cardiac muscle cell development GO:0061051 9.54 MIR19A MIR199A1
15 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.46 MIR20A MIR17
16 gene silencing by miRNA GO:0035195 9.44 MIR9-1 MIR34C MIR34A MIR338 MIR27A MIR20A
17 negative regulation of sprouting angiogenesis GO:1903671 9.35 MIR34C MIR34A MIR20A MIR19A MIR17

Molecular functions related to Peripheral Nervous System Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR9-1 MIR34A MIR338 MIR27A MIR20A MIR19A

Sources for Peripheral Nervous System Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....